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Abstract 
 
 
 
 
Memory deficits may develop from a variety of neuropathologies including Alzheimer’s 
disease dementia. During neurodegenerative conditions there are contributory factors such 
as neuroinflammation and amyloidogenesis involved in memory impairment. In the present 
study, dual properties of S100A9 protein as a pro-inflammatory and amyloidogenic agent 
were explored in the passive avoidance memory task along with neurochemical assays in the 
prefrontal cortex and hippocampus of aged mice. S100A9 oligomers and fibrils were 
generated in vitro and verified by AFM, Thioflavin T and A11 antibody binding.  Native 
S100A9 as well as S100A9 oligomers and fibrils or their combination were administered 
intranasally over 14 days followed by behavioural and neurochemical analysis. Both 
oligomers and fibrils evoked amnestic activity which correlated with disrupted prefrontal 
cortical and hippocampal dopaminergic neurochemistry. The oligomer-fibril combination 
produced similar but weaker neurochemistry to the fibrils administered alone but without 
passive avoidance amnesia. Native S100A9 not modify memory task performance even 
though it generated a general and consistent decrease in monoamine levels (DA, 5-HT and 
NA) and increased metabolic marker ratios of DA and 5-HT turnover (DOPAC/DA, 
HVA/DA and 5-HIAA) in the prefrontal cortex. These results provide insight into a novel 
pathogenetic mechanism underlying amnesia in a fear-aggravated memory task based on 
amyloidogenesis of a pro-inflammatory factor leading to disrupted brain neurochemistry in 
the aged brain. The data further suggests that amyloid species of S100A9 create deleterious 
effects principally on the dopaminergic system and this novel finding might be potentially 
exploited during dementia management through a neuroprotective strategy. 
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1. Introduction 
 
There is now growing evidence suggesting that in Alzheimer's disease (AD) 
neuroinflammation is one of the cardinal pathogenic features accompanied by the 
accumulation of amyloid-β protein (Aβ) in extracellular plaques and deposition of 
hyperphosphorylated tau protein in intracellular neurofibrillary tangles [1-3]. Furthermore, 
AD has largely been characterized by a severe deterioration of cognitive function [4] but the 
causal cellular and molecular mechanisms of cognitive decline are still subject to debate and 
endeavour [5,6]. Some members of the S100 protein group of which there are ≤ 24 examples 
[7,8] such as S100B [9,10], S100A1 [11], S100A8, S100A9 and the S100A8/A9 complex 
[12] are thought to be implicated in AD pathogenesis [13]. It is also noteworthy that 
S100A8/S100A9 and its complex are recognised as potent stimulators of neutrophil 
migration into inflammatory sites [14]. Explicitly in neural tissues, S100A9 protein is 
understood to modulate inflammation because it is prevalent within neuritic plaques as well 
as reactive glia and these days, it is continuously acknowledged as an influential contributor 
to inflammation-linked neurodegenerative states like AD [12,15,16]. Accordingly, it has 
been demonstrated that S100A9 brain expression is increased not only in AD mouse models 
but also in human AD sufferers [12]. The instrumental role of inflammation in AD is further 
supported by a sharp induction of inflammatory mediators in AD-affected brains [17] in 
addition to epidemiological and experimental studies which demonstrate that non-steroidal 
anti-inflammatory drugs markedly reduce the age-related prevalence of AD [18]. Since 
S100A9 is highly abundant in AD brains, it may well be a key element in AD progression 
due to its inherent amyloidogenicity [16,19] and it has been reported that intrinsically 
disordered prone molecular regions underlie β-aggregation of the S100 proteins [20].  
The amyloid pathway is known to play a crucial role in AD pathogenetic processes [21] so 
the discovery that S100A9 is abundant in tissues surrounding amyloid deposits in AD brains 
is highly suggestive that an elevation of S100A9 levels favours its aggregation and 
deposition [16]. In animal studies, evidence has been presented that the inflammation-related 
S100A9 gene is significantly up-regulated in the brains of Tg2576 and CT-Tg AD mouse 
models as well as in AD patients. In addition, experiments have shown that knockdown of 
S100A9 expression improves cognitive function in the Tg2576 AD mouse and these animals 
correspondingly exhibit a reduced amyloid plaque burden [22]. Moreover, crossbreeding of 
Tg2576 mice with S100A9 knockout mice (S100A9KO/Tg2576) enhances visuospatial 
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reference memory and diminishes Aβ neuropathogenesis as evidenced by reduced levels of 
Aβ, C-terminal fragments of amyloid precursor protein (APP-CT) and phosphorylated tau 
compared to age-matched S100A9WT/Tg2576 controls. Commensurate with these findings, 
there was an increase in expression of anti-inflammatory IL-10 and decreased expression of 
inflammatory interleukin 6 as well as tumour necrosis factor-α [23]. These results clearly 
show that the up-regulation of the S100A9 gene plays an important role in the 
neuropathology and memory impairment in AD [12] as well as the neurodegeneration and 
cognitive deficits seen in Tg2576 mice [23]. 
 
In addition, AD pathology is even more intricate since in parallel with neuroinflammation 
and protein neuroaggregation, there are consequentially perturbed neurotransmitter 
signalling processes [24]. Thus, studies have disclosed links between morphological and 
functional changes occurring in ascending monoaminergic systems such as noradrenergic 
and serotonergic pathways with respect to AD pathophysiology [25,26]. In association with 
symptoms of cognitive decline, about 35–40% of AD patients present with extrapyramidal 
signs, reinforcing the idea that dopamine (DA) containing neurons undergo degenerative 
changes [24,27]. Furthermore, the use of dopaminergic D2 agonist drugs like rotigotine, 
have manifested beneficial effects on some cognitive domains in AD patients [28]. What is 
more, changes in various correlates of cholinergic, monoaminergic and amino acid 
neurotransmitter systems, as well as neuropeptides, have recently been appraised in the CSF 
of AD patients [29].  
 
Information concerning potential interactions of S100A9 amyloid species with 
neurotransmitter pathways is unavailable in the literature although it is known that native 
S100A9 interacts with Aβ(1–40) peptide and promotes the formation of fibrillar β-amyloid 
structures [30]. Protofilaments of S100A9 themselves are highly neurotoxic and inflict rapid 
damage and death to neurons. Due to the fact that combined aggregation of S100A9 with Aβ 
peptide proceeds more efficiently than the separate counterparts, the co-aggregation process 
may act as an emergency sink, rapidly removing systemic neurotoxic amyloid species of 
both polypeptides.  On top of this, native S100A9 is a ligand at both Toll-like receptors 
(TLRs) and the receptor for advanced glycation end products (RAGE), the latter being 
involved in the recognition of endogenous molecules released during chronic inflammation 
[16,31,32]. The consequence of this clearance process however, can be the exacerbated 
growth of amyloid plaques in the AD brain. It is known from previous studies that amyloid 
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complexes of S100A9 are much more stable and protease resistant compared to amyloid 
species of other proteins [33] and their clearance and removal may be therapeutically less 
favorable. Furthermore, the plaques themselves may aggravate microglial activation, thus 
completing a vicious circle of the amyloid-neuroinflammatory cascade [16]. On the other 
hand, the formation of amyloid plaques may act as a depository for toxic species, and the 
process may derive from of a protective response within the brain of AD patients, in part 
mediated by S100A9 itself [30]. It is clear that because of its amyloidogenic propensity, 
neurotoxicity and signalling functions, native S100A9 and its misfolded species may be 
capable not only of modifying memory and learning processes but also of impairing them 
via a pro-inflammatory origin. The aim of this study therefore was primarily to investigate 
the effects of exogenous intranasal administration of native S100A9 as well as in vitro 
generated oligomers and fibrils or their combination on passive avoidance learning and 
memory along with monoamine neurotransmitter metabolism in cerebral structures of aged 
mice. 
 
 
 
 
 
2. Materials and Methods 
2.1. Subjects 
Adult male C57Bl/6 mice aged 12-months and weighing 31.1±1.0g were used throughout. 
The animals were group housed on a 12:12 light-dark cycle at a constant temperature of 
21oC and 50% humidity with access to food and water ad libitum. All experimental 
procedures were carried out in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996); the UK 
Animals Scientific Procedures Act 1986 and associated guidelines; the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) for care and use of 
laboratory animals. They were also approved by the Animal Care and Use Committee of the 
P. K. Anokhin Research Institute of Normal Physiology. 
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2.2. Procedures and dosing protocol 
Experiments were performed between 10.00-15.00 hours and animals were divided into five 
groups (n = 14 per group) which underwent the protocol chronology shown in Fig. 1. (Group 
1; naïve control) was administered saline vehicle intranasally (i.n) in alternate nostrils daily 
in a total volume of 8 µL/animal daily (i.e. 4 µL/nostril using a Hamilton syringe) over a 
total dosing period of 14-days. Group (2) was administered a solution of native S100A9 
(15.0 µg in 8 µL = 0.48 mg/kg) using the same 14-day dosing schedule. Group (3) received 
oligomeric aggregates (15.0 µg in 8 µL = 0.48 mg/kg) using the 14-day dosing schedule. 
Group (4) was dosed with S100A9 fibrillar aggregates (15.0 µg in 8 µL = 0.48 mg/kg) for 
14 days. Group (5) was co-administered aggregates of S100A9 oligomers plus fibrils 
simultaneously each in a 50%:50% concentration of 7.5µg in 4 µL/animal bilaterally 
alternating the nostril receiving each aggregate species (i.e. total α-syn equivalent dose 15 
µg = 0.48 mg/kg i.n.) over the 14-day protocol. At the end the 14-day protocol (i.e. on day 
15), animal groups 1-5, underwent behavioral testing. The next day they were killed and 
neurochemical analysis of the hippocampus and prefrontal cortex was performed (n = 7 per 
group). All behavioral tests and neurochemical analyses were performed under blind 
conditions. 
 
 
Fig. 1. Scheme showing the chronology of the intranasal S100A9 dosing protocol, passive avoidance 
training and retention sessions then the post mortem hippocampal and prefrontal cortical sampling 
period in 12-month old C57Bl/6 mice prior to neurochemical analysis.  
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2.3. Production of S100A9 protein 
S100A9 was expressed in E coli and purified as described previously [34]. Its concentration 
was determined by using ε280 = 0.53 (mg/ml)−1 cm−1 . 
 
 
 
2.4. Production of S100A9 amyloid species  
In order to avoid the presence of the preformed aggregates in S100A9 solution, the protein 
was initially dissolved in 10 mM PBS buffer, pH 7.4, subjected to 15 min sonication, then to 
15 min centrifugation at 14,000 rpm in a minicentrifuge (Eppendorf Centrifuge 5417R) and 
the supernatant collected from the upper layer was filtered through a 0.22 um filter (Millex). 
The final solution was incubated at a 2.0 mg/ml concentration in 10 mM PBS buffer, pH 7.4, 
37 oC, using continuous agitation at 600 rpm (Eppendorf Thermomixer Compact). Amyloid 
oligomers and fibrils of S100A9 were produced after 2h and 24h of incubation, respectively. 
The oligomeric sample was lyophilized for storage and reconstituted in PBS buffer prior to 
dosing while the fibrillar sample was stored at 4 °C prior to administration. The 
morphological parameters of reconstituted oligomers were compared with freshly produced 
structures using AFM imaging and they were confirmed to be essentially unchanged. 
 
2.5. Fluorescence assay 
The Thioflavin T (ThT) binding assay was performed using a modification of LeVine’s 
method [35]. Thioflavin T fluorescence was measured by a Jasco FP-6500 
spectrofluorometer (Jasco, Japan), using excitation at 440 nm and collecting the emission 
between 450–550 nm, with excitation and emission slits set at a 5 nm width. 
2.6. Atomic force microscopy (AFM) assay 
Atomic force microscopy (AFM) imaging was carried out by a BioScope Catalyst AFM 
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(Bruker) in the peak force mode in air at a resonance frequency of ca. 70 kHz and a 
resolution of 256 x 256 pixels; scan sizes ranged from 0.5 to 10 μm. Amyloid samples were 
deposited on the surface of freshly cleaved mica (Ted Pella) for 15 min, washed 3 times with 
100 μl deionized water and dried at room temperature and then subjected to AFM analysis 
(Fig. 2). 
 
2.7. Behavioural tests 
2.7.1. Passive avoidance test 
Behavioral analysis was performed in all animal groups (n = 14 per group) one day after the 
end of the native S100A9 or its amyloidgenic species dosing protocol (i.e. day 15). Passive 
avoidance performance was investigated using a training apparatus which consisted of a 
rectangular chamber divided into two compartments (PACS two-way Shuttle box, Columbus 
Instruments, USA). One compartment was lit by an overhead light stimulus and the other 
side remained in darkness. The two compartments were separated by an automatic guillotine 
door and each had a grid floor through which footshock could be delivered. One-trial 
passive avoidance tests were performed as previously described [36,37]. Briefly, each 
animal was introduced singly into the light compartment of the light-dark box. During 
habituation, mice were allowed to freely explore the box for 5 min with the sliding door 
between the light and dark compartments open and subsequently, they were returned to their 
home cage. On the training day, each animal was placed into the lit compartment, facing 
away from the dark compartment and allowed to explore for 30s then the guillotine door was 
lifted. Upon animal entry into the dark compartment with all four paws, the guillotine door 
was then closed, and the entry latency recorded (from the time the door was lifted). Three 
seconds after door closure, a footshock (0.5 mA, 3 seconds duration) was delivered and 30s 
later each mouse was removed to its home cage. Animals which did not enter the dark 
compartment within 180s underwent another session of training on the same day. Tests were 
carried out 24h after conditioning by re-introducing animals into the light compartment of 
the apparatus and the latency of mice entering the dark compartment was recorded (light-
dark latency, with a 5 min cut-off). The 24h postconditioning tests were carried out in all 
experimental animal groups. 
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2.7.2. Open field exploratory test 
Animal behavioral analysis was performed on all groups (n=10) one day following the 
S100A9 species and control dosing protocols (i.e. day 15) and a total of five behavioral 
indicators of emotionality as well as qualitative and quantitative measures of general 
locomotor activity were evaluated [38,39]. Firstly, hypokinesia was assessed by quantifying 
open field spontaneous locomotor activity based on previous methodologies [40,41] for a 
period of 0-6 min after 5 min acclimatization in an animal activity meter (Opto-Variomex-3 
Auto-Track system, Columbus Instruments, Columbus, Ohio, USA). The 0-6 min recording 
time was chosen since it represented an optimal period for detecting neurotoxin-induced 
locomotor hypokinesia in 3-minute epochs up to a total of 30 minutes in C57Bl/6 mice [42]. 
Additionally, total locomotor distance, cumulative ambulation time plus speed (horizontal 
activity measures) and vertical rearing (vertical activity measure) along with immobility time 
were recorded. Secondly, muscle rigidity was gauged using a “gibbosity” test manifested by 
the shortening of the neck to the tailbase measurement and scored by the following scoring 
scale: (0) = no rigidity; (1) = 1.0cm decrease; (2) = 2.0cm decrease; (3) = >2.0cm decrease 
[42]. Thirdly, the presence or absence of tremor was checked behaviourally [43] using the 
following scoring scale: (0) = no tremor; (1) = head tremor; (2) = head and forepaw tremor, 
(3) = whole body tremor. Lastly, assessment of anxiety-like behavior was also included in the 
form of a fecal boli count for all groups [44]. 
 
2.8. Neurochemical determination of the tissue content of DA, 5-HT and their metabolites 
(DOPAC, HVA and 5-HIAA as well as NA in mouse brain structures by high 
performance liquid chromatography with electrochemical detection (HPLC/ED) 
Hippocampal and prefrontal cortical mouse brain structures were dissected on ice (40C) then 
weighed and immediately stored in liquid nitrogen for subsequent analysis. Tissue samples 
were homogenized in 0.1 N perchloric acid (1:20) with 0.5 μM 3,4-dihydroxybenzoic acid 
as internal standard and centrifuged (10,000g  x 10 min, 40C; Eppendorf 5415 R, Germany). 
The supernatant was analyzed by high performance liquid chromatography with 
electrochemical detection (HPLC/ED) [45]. DA and its metabolites, DOPAC, and HVA as 
well as 5-HT, 5-HIAA and NA were detected using a glassy carbon electrode set at +0.85 V 
compared with an Ag/AgCl reference electrode using an electrochemical detector LC-
4B (Bioanalytical Systems, West Lafayette, Indiana, USA). The mobile phase contained 0.1 
M citrate-phosphate buffer (pH 2.9), 1.85 mM 1-octanesulfonic acid, 0.27 mM 
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ethylenediaminetetra-acetate (EDTA) and 8% acetonitrile and pH was adjusted to 3.0 with 
6M KOH. All reagents used for the mobile phase were of analytical grade (Sigma-Aldrich, 
USA) and samples were filtered through a 0.22 μm nylon filter (Merck Millipore, Merck 
KGaA, Germany). DA, 5-HT and their metabolites as well as NA were separated by an 
analytical reverse-phase column on reprosil C18, pore size 4 μm, 100 x 4 mm. (Dr. Maisch, 
GMBH) at a flow rate of 1.0 ml/min.  
 
2.9. Statistics 
Results were statistically processed using Statistica 7.0 software. The distribution of 
behavioral data did not conform to a normal distribution (Lilliefors test, P<0.01) and thus, 
univariate nonparametric analysis of variance Kruskal-Wallis test (H-criterion) with by post-
hoc analysis by the Mann-Whitney U test was performed. Data are presented as mean ± 
s.e.m. The critical level of statistical significance in the test for the null hypothesis was 
accepted at P<0.05. 
 
 
 
3. Results  
3.1. Characterization of S100A9 oligomeric and fibrillar aggregates 
The samples containing S100A9 oligomers were collected after 2h of incubation. They were 
characterized by a 1.3-fold increase in Thioflavin T fluorescence compared to freshly 
dissolved native S100A9. The oligomers of S100A9 displayed a round-shaped morphology 
assessed by AFM imaging with an average height measured by AFM cross-section analysis 
of 1.0nm (Fig. 2A, B). Some small and coiled protofilaments of ca. 100 nm in length were 
also noticed in the sample, some of them were locked into ring-type structures of a 50 to 100 
nm diameter. Fibrillar structures were developed after 24h of incubation under the same 
conditions. They displayed typical fibrillar morphology with ca. 3 nm height as determined 
in AFM cross-sections (Fig. 2C, D) and were characterized by a 5.6-fold increase in 
Thioflavin T fluorescence intensity (Fig. 2E).  The S100A9 fibrils were very flexible and 
coiled, existing separately and also coiled into some superstructured coils and clumps. The 
oligomeric nature of these species was verified by interaction with generic A11 antibodies 
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reactive towards S100A9 amyloid oligomers and fibrils [46]. 
 
Fig. 2. In vitro characterisation of S100A9 amyloid species 
AFM height images of S100A9 amyloid (A) oligomers and (C) fibrils formed after 2 h and 24 h 
of incubation under the same conditions, Scale bars are both 220 nm.                        
Cross-sectional analysis of representative amyloid (B) oligomers and (D) ring-type fibrils. (E) 
Thioflavin T fluorescence intensity of S100A9 amyloid development with respect to time (min). 
 
3.2. Behavioural data 
3.2.1. Passive avoidance performance of aged mice treated intranasally (i.n.) with saline 
vehicle, native S100A9, oligomers, fibrils and an oligomeric plus fibrillar mixture for 14 
days 
The passive avoidance performance activity of mice treated for 14-day i.n. with native 
S100A9, oligomers, fibrils and the oligomer/fibrillar mixture in comparison with saline 
vehicle treated controls is shown in Fig. 3.  There was a +343.5% (P<0.01) increase in 
latency in the retention session compared to the first day training session in the control 
group. 
In the native S100A9 treated group, there was no statistical difference in mean latencies 
versus the control group retention latency or the difference (Δ) between first day and retention 
day latencies. However, in the group administered S100A9 oligomers, the first day latency 
was 2.56 fold higher than the controls and this latency persisted during retention such that the 
12 
 
Δ latency was markedly lower than controls (P<0.01). A similar outcome was observed in the 
S100A9 fibril dosed group in that there was a highly significant Δ latency difference (P<0.01) 
from the vehicle treated controls. In the case of animals receiving the oligomeric/fibrillar 
mixture there was no difference from controls throughout (Fig. 3). Analysis of variance for 
the passive avoidance task latency on the 1st training day revealed a statistically significant 
difference between animal groups after 14 day intranasal inoculation with native S100A9, 
S100A9 aggregates or their mixture in comparison with the control group 
(H(4N=50)=15.84345, P=0.0032). On the 2nd day (retention) analysis of variance for the 
passive avoidance task latencies between experimental groups and controls disclosed 
significance (H(4N=50)=9.807386, P=0.0438) and in addition, evaluation of passive 
avoidance Δ latencies versus controls also yielded significance (H(4N=50)=27.17050, 
P<0.001).  
3.2.2. Open field exploratory activity of aged mice treated intranasally (i.n.) with saline 
vehicle, S100A9 oligomers or fibrils for 14 days 
After 14 day intranasal treatment with saline vehicle and S100A9 oligomers or fibrils, no 
significant behavioral differences between the S100A9 species treated group responses versus 
control were detected in total locomotor distance (H (2, N=30) =2.006947 (P=0.3666), 
cumulative ambulation time (H (2, N= 30) =3.829396 (P =0.1474), immobility time (H ( 2, 
N= 30) =4.761425 (P =0.0925), ambulation speed (H (2, N= 30) =2.029224 (P =0.3625) or 
vertical rearing (H (2, N= 30) =0.8797098 (P =0.6441) (Table 1). Neither was there evidence 
of rigidity identified in any of the groups using the established scoring scale and none of the 
animals exposed to the open field paradigm displayed any significant differences in fecal boli 
counts. Thus, it was confirmed that intranasal administration of the S100A9 aggregates was 
devoid of any anxiety-like behavioral outcome in an open-field environment.   
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Fig. 3. Behavioural effects of intranasal dosing with S100A9 species in 12-month old C57Bl/6 
mice on the passive avoidance task 1st day (training) and 2nd day (retention) latencies (s) plus the 
latency differences (∆ latencies, s). 
Animal groups (n = 14) were intranasally administered saline or S100A9 species daily for 14 
days and passive avoidance performance was tested on protocol days 15 (1st day - training) and 
day 16 (2nd day - retention). *P< 0.05; **P<0.01 compared with control. 
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3.3. Neurochemical assay of hippocampal NA, 5-HT and the metabolite 5-HIAA after 14-
day treatment with S100A9 monomers, oligomers, fibrils and the oligomer/fibril mixture 
There were no significant changes in NA, 5-HT or 5HIAA levels in hippocampal tissues in 
all animal groups treated with S100A9 species (Table 2).  
 
 
 
3.4. Neurochemical assay of hippocampal DA and the metabolites DOPAC, HVA after 14-
day treatment with native S100A9, oligomers, fibrils and the oligomer/fibril mixture 
There was a -49.5% (P<0.05) decrease in DA levels in the hippocampus induced by 14-day 
i.n. treatment with S100A9 oligomers but in contrast, mice dosed with S100A9 fibrils 
displayed an increase in DA levels (+44.1%, P<0.05) (Fig. 4). No significant changes were 
noted in response to native S100A9 two week treatment although the HVA concentration in 
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the hippocampus was doubled (P<0.01) following native S100A9 chronic dosing (Fig. 4). 
The hippocampal DA content in the animal group chronically treated with the 
oligomeric/fibrillar combination displayed a reduction of 25% in contrast there were no 
significant changes in HVA level in response to oligomeric or fibrillar treatment. In all 
groups of animals there were no detectable alterations in hippocampal DOPAC 
concentrations (Fig. 4). 
 
 
Fig. 4. Hippocampal levels of DA, HVA and DOPAC measured in 12-month old C57Bl/6 mice 
following intranasal dosing with S100A9 species. 
Animal groups (n=14) were intranasally administered saline or S100A9 species daily for 14 days and 
hippocampal DA, HVA and DOPAC levels were measured as % of control (DA control = 0.28 ± 
0.11 nM/g of tissue; HVA control = 0.11 ± 0.03 nM/g of tissue; DOPAC control = 0.38 ± 0.10 nM/g 
of tissue).  
*P< 0.05 compared to control. 
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3.5. Neurochemical assay of prefrontal cortical NA, 5-HT and the metabolite 5-HIAA 
after 14-day treatment with native S100A9, oligomers, fibrils and the oligomer/fibril 
mixture 
In the case of NA levels in the prefrontal cortex, only treatment with native S100A9 evoked 
a statistically significant decrease (-45.6%, P<0.05) (Table 3). In all other S100A9 species 
treated groups, there were no significant changes in NA concentration in the prefrontal 
cortex. Moreover, monomeric S100A9 administration reduced the 5-HT content by -46.3% 
(P<0.05) in the prefrontal cortex (Table 3) whereas oligomers, fibrils or their combination 
respectively varied 5-HT levels by +15.4%, +12.9% or +17.0% though none of these 
fluctuations achieved statistical significance (Table 3). 
Native S100A9 administration decreased (-45.5%, P<0.05) prefrontal cortical levels of 5-
HIAA (Table 3). Conversely S100A9 fibrillar treatment did not cause any significant change 
in 5-HIAA concentration and neither did the oligomers nor the combinative treatment have 
any influence on levels of this metabolite. 
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3.6. Neurochemical assay of prefrontal cortical DA and the metabolites DOPAC, HVA 
after 14-day treatment with native S100A9, oligomers, fibrils and the oligomer/fibril 
mixture 
Two week nasal administration of native S100A9 produced a fall (-37.8%, P<0.05) in DA 
prefrontal cortical concentration and S100A9 oligomer treatment gave a similar decrement (-
30.2%, P<0.05). Conversely, S100A9 fibril or oligomer/fibril combination dosing had no 
significant effect on DA levels. Native S100A9 reduced cortical DOPAC concentrations (-
46.2%, P<0.05) whilst S100A9 fibrils increased DOPAC levels (+19.6%, P<0.05) but 
combinative fibril/oligomer administration had no significant action on DOPAC prefrontal 
cortical level (Fig. 5). 
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Fig. 5. Prefrontal cortical levels of DA, HVA and DOPAC measured in 12-month old C57Bl/6 
mice following intranasal dosing with S100A9 species. 
Animal groups (n= 14) were intranasally administered saline or S100A9 species daily for 14 
days and prefrontal cortical DA, HVA and DOPAC levels were measured as % of control (DA 
control = 1.72 ± 0.42 nM/g of tissue; HVA control = 0.41 ± 0.05 nM/g of tissue; DOPAC 
control = 0.78 ± 0.06 nM/g of tissue). *P< 0.05 compared to control.  
 
 
3.7. DOPAC/DA, HVA/DA and 5-HIAA/5-HT ratios in the hippocampus of mice after 14-
day intranasal treatment with S100A9 monomers, oligomers, fibrils and the 
oligomer/fibril mixture 
The hippocampal DOPAC/DA ratio following S100A9 oligomer two-week intranasal 
delivery produced an increase (+124.3%, P<0.01) in this parameter while the combination of 
S100A9 oligomer plus fibril treatment decreased this ratio by -27.8% (P<0.05). Neither 
native S100A9 nor fibrils modified the DOPAC/DA ratio in the hippocampus (Fig. 6A).  
Native S100A9 induced an increment in hippocampal HVA/DA ratio (+52.8%, P<0.05) 
along with a S100A9 oligomer boost in this ratio (+172.2%, P<0.01) (Fig. 6A). The fibrils 
of S100A9 also augmented (+53.7%, P<0.05) HVA/DA ratio whilst the oligomer/fibril 
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combination had no effect (Fig. 6A). In comparison with controls, there were no 5-HIAA/5-
HT ratio hippocampal changes in any of the S100A9 species treated animals (Table 2). 
 
3.8. DOPAC/DA, HVA/DA and 5-HIAA/5-HT ratios in the prefrontal cortex of mice after 
14-day intranasal treatment with S100A9 monomers, oligomers, fibrils and the 
oligomer/fibril mixture 
Following native S100A9 administration, a decrease (-35.8%, P<0.05) in DOPAC/DA ratio 
occurred in the prefrontal cortex but the S100A9 oligomer/fibril combination produced a 
+72.5% (P<0.05) increase (Fig. 6B). 
Intranasal delivery of native S1009 decreased the prefrontal cortical HVA/DA ratio by -
38.8% (P<0.05). In contrast, fibrils of S100A9 elevated the HVA/DA ratio (+42.3%, 
P<0.05) and the oligomer/fibril mixture also evoked an increase (+40.7%, P<0.05) (Fig. 6B).  
Fourteen day administration of native S100A9 did not alter prefrontal cortical 5-HIAA/5-HT 
ratios compared to controls (Table 3). However, delivery of S100A9 oligomers, fibrils and 
their combination all induced respective escalations compared to controls of +34.3%, 
+41.1% and +34.4% (P<0.05) in these ratios reflecting an apparent increased 5-HT turnover 
in response to these particular species within the prefrontal cortex (Table 3). 
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Fig. 6. (A) Hippocampal and (B) prefrontal cortical  DOPAC/DA and HVA/DA ratios calculated for 
12-month old C57Bl/6 mice following intranasal dosing with S100A9 species. 
Animal groups (n=14) were intranasally administered saline or S100A9 species daily for 14 days and 
hippocampal and prefrontal cortical DOPAC/DA and HVA/DA ratios were calculated as % of 
control (All controls = 100%). *P< 0.05; **P< 0.01 compared to control. 
 
 
4. Discussion    
Memory deficits may develop from a variety of neuropathologies and the pathological self-
assembly of proteins and peptides into amyloid species is a defining characteristic of a group 
of more than twenty human diseases [47-49] including neurodegenerative conditions such as 
AD [50]. The amyloid hypothesis postulates that proteins which undergo aberrant 
physiological folding generate toxic oligomeric species capable of inducing a decline in 
synaptic plasticity, perturbation of neuronal networks and cell death [24,51] instigating 
cognitive dysfunction. Moreover, along with oligomeric species, amyloid fibrils are 
invariably present in affected biosystems. Many studies have shown that soluble oligomeric 
assemblies, which either precede amyloid formation or exist as stand-alone species are 
formed in parallel with fibrils to exert the most potent detrimental physiological effects [52]. 
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In the case of AD, aggregation of Aβ peptide has been identified and is initiated by the 
misfolding of the native protein monomer into an amyloid form of insoluble fibrils. 
Additionally, fibrillar (but not native) forms of Aβ peptide which are akin to those present in 
AD amyloid plaques, are toxic in neuronal cell culture [53,54]. However, a relatively weak 
association has been unveiled between fibrillar plaque density in AD brains and dementia 
severity, whereas correlations between soluble Aβ levels and the extent of synaptic loss 
coupled with cognitive impairment are somewhat stronger [54,55]. SDS-stable Aβ 
oligomers (relative molecular masses Mr ≈ 8,000 and 12,000) have been detected by 
Western blotting in the buffer-soluble fraction of AD cortical areas [56]. It has also been 
reported that Aβ oligomers, in the absence of monomers and amyloid fibrils, disrupt 
synaptic plasticity in vivo at concentrations corresponding to those found in human brain 
and cerebrospinal fluid [54]. Subsequently, it was proposed that cerebral amyloidosis 
predicts longitudinal episodic memory decline in presymptomatic AD but multidomain 
cognitive decline in the symptomatic AD stage. Findings of this nature imply that 
amyloidosis in the brain is an indicator of early cognitive decline and they provide a useful 
outcome measure for early assessment and prevention treatment trials [21]. In this 
connection, the observation that S100A9 is abundant in tissues surrounding amyloid 
deposits in AD brains is highly suggestive that an elevation of S100A9 favours its 
aggregation and deposition [16,19,57].  
After 14-days of native S100A9 treatment, there were no significant changes in passive 
avoidance latency, on the test day. Concomitantly, neither locomotor activity nor 
emotionality (anxiety-like behavior) was perturbed in any of the treatment groups so the 
passive avoidance disruption induced by S100A9 aggregates during retention was an 
exclusive cognitive phenomenon. Simultaneously, in the prefrontal cortex, the overall 
neurochemical response was represented by a decrease in levels of DA, 5-HT, their 
respective metabolites DOPAC and 5-HIAA as well as NA in addition to DA turnover 
(DOPAC/DA and HVA/DA ratio). This finding was in contrast with the neurochemical 
outcome in the hippocampus where an increase in HVA/DA ratio indicated an elevation of 
DA turnover. It is likely that these neurochemical outputs originate from pro-inflammatory 
effects of native S100A9 protein [14,16]. It may be deduced therefore that chronic intranasal 
administration of monomeric S100A9 initiated an inflammatory response which then 
yielded the observed neurochemical changes in the affected brain structures.  
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In fact, we have previously demonstrated that S100A9 can act as a link between the amyloid 
and inflammatory cascades [16] and during AD plaque formation microglia become activated 
and recruited to the plaque deposition sites [58] causing microgliosis. The activated microglia 
secrete S100A9 as well as an array of other pro- and anti-inflammatory mediators. This can 
contribute to changes in neuronal calcium homeostasis [59,60]. As a result, S100A9 
expression in neuronal cells can also be turned on, which further activates microglia via the 
toll-like receptor 4 (TLR 4) and the receptor for advanced glycation end products (RAGE) 
signaling pathway [61,62] there being an inflammatory repercussion.  
 
Experimental evidence has shown that in animal models of AD, mechanisms of cortical 
plasticity such as long-term potentiation (LTP) and long-term depression (LTD) are 
impaired, but in AD patients, LTP-like cortical plasticity is abolished whereas LTD seems to 
be preserved [28]. In the present case of S100A9 monomeric treatment of aged animals, 
despite there being a neurotransmitter malfunction, both mechanisms may not have yet been 
invoked.  Hence, passive avoidance memory deficiency was not discernible in the current 
protocol, even though the prefrontal cortex is a brain area which is crucial for memory, 
attention, and decision making [63]. It could be reasoned that S100A9 monomers initiated 
inflammation to set off the prefrontal cortical neurochemical dysfunction which may in turn 
affect the functional connectivity between the hippocampus and prefrontal cortex known to 
be essential for memory formation [64-66].  
The most striking effects were observed in the animal group with intranasally administered 
misfolded species of S100A9 protein. In the passive avoidance paradigm, mice which 
received S100A9 oligomeric structures expressed an increment of passive avoidance latency 
on the training day in comparison with controls though this difference was not maintained 
24h later in the testing procedure. Passive avoidance amnesia in this instance was associated 
with a decrement of DA concentration in both the prefrontal cortex and the hippocampus 
which was also accompanied by an increase in hippocampal DA turnover. Such concomitant 
neurochemical consequences substantiate the involvement of these neuroanatomical 
structures in processes underlying passive avoidance amnesia and identify the participation 
of DA-ergic pathways. The part played by the DA-ergic system in learning and memory 
mechanisms is recognized and DA transmission has been hypothesized as a governing factor 
for mechanisms of cortical plasticity in AD [28]. It also performs dual protective and toxic 
roles during neurodegeneration [67].  
24 
 
DA has wide-ranging effects on both cortical and subcortical brain regions and on many 
types of cognitive task that rely on a variety of different learning and memory systems [68]. 
Consideration of these details inevitably leads to different postulations as to how changes in 
brain dopamine metabolism following intranasal S100A9 oligomer administration cause 
passive avoidance memory impairment. In this case, it is appropriate to point out that the 
toxicity of S100A9 oligomers together with DA-ergic adverse effects are the foremost 
integral components of amnestic activity rather than the initial pro-inflamatory properties of 
the native protein monomers. It is becoming increasingly evident that deficits in the cortex 
and hippocampus during the early stages of AD dementia are associated with synaptic 
damage caused by toxic oligomers of amyloid-β peptide (Aβ1-42). In light of this, a novel 
mechanism has been designated for the regulation of synaptic transmission by Aβ1-42 via 
disruption of the interaction between synaptophysin and vesicle-associated membrane 
protein 2 (VAMP2) [69]. Not long ago, it was reported that Aβ peptide in AD patients 
induces both metabolic and morphological changes in pyramidal neurons in the 
hippocampus and neocortex. Prefrontal and cingulate cortices together with the 
hippocampus also express changes during the early stage of the disease and are responsible 
for symptoms of cognitive decline [24,70]. Sub-cortical nuclei, 5-HT, NA and DA-
containing neurons constitute the monoaminergic ascending diffuse innervating system that 
synapses onto hippocampal and neocortical neurons, with several modulatory effects on 
neuronal firing [26]. Neuropathological studies have established a link between 
morphological and functional changes occurring in this monoaminergic ascending system, 
particularly in respect of NA and 5-HT pathways and the pathophysiology of AD [24-26]. In 
association with symptoms of cognitive decline, about 35–40% of AD patients present with 
extrapyramidal signs, supporting the concept that DA-containing neurons undergo 
degenerative changes [24,27].  
Fibrillar S100A9 14-day treatment induced passive avoidance memory retention deficits in 
87.3% of the animals which correlated with an enhancement of DA turnover in the 
prefrontal cortex, an increased DA level in the hippocampus and elevation of HVA/DA 
ratio. DA is a multifaceted neurotransmitter and different degrees of DA dysfunction can 
occur during the phases of AD [24]. Correspondingly, in the current study it was 
unequivocally demonstrated that S100A9 species influenced the DA-ergic system 
differentially. Furthermore, DA not only provides communication between nerve cells but it 
is implicated in motor control. If this signal transmission becomes disturbed, the 
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consequences can be dramatic and this is illustrated by PD, the symptoms of which include 
akinesia and other movement disorders which can be traced back to a lack of DA [71]. It 
could be argued that a motor deficit might interfere with performance in the passive 
avoidance task but in this study there was no overt evidence of any decreased spontaneous 
locomotor activity to S100A9 aggregates. There have already been indications of the special 
role of DA and its receptors in forming long-lasting memories. For example, activation of 
the prefrontal cortical, striatal, and hippocampal dopamine DA1- family of receptors (D1 but 
not D5 receptors) is necessary for normal spatial information processing [72]. Reduced DA 
transporter (DAT) expression in the caudate putamen, hippocampus and frontal cortex has 
been described during human brain aging [73] and DAT has also been hypothesized as a 
possible target of amyloid insult [63]. Thus, an influence of S100A9 aggregates on DAT 
function cannot be excluded as one of the elements of DA disrupted function in spatial 
memory [74]. 
It may also be hypothesised that S100A9 fibrillar deposits in AD possess inflammatory 
properties which are linked to their intrinsic structure, most probably their cross-β sheet 
structure similar to other species of protein fibrils, for example, α-synuclein in PD. Since 
fibrils of other amyloids induce analogous immunological responses, it has been proposed 
that the acknowledged fibril specific cross-β sheet structure represents a generic motif 
recognized by the innate immune system [75]. In the case of the amnesia caused by S100A9 
fibrils, it may be suggested that fibrillar incited inflammation [76] or injury interferes with 
DA metabolism thereby contributing to memory impairment so a DA-ergic dysfunction may 
well be involved in cognitive decline [24]. 
Indeed, experimental data from transgenic AD mice showed how DA-ergic pathology and 
amyloid deposition are closely related, suggesting a causative effect of amyloid on 
dopamine dysfunction [77]. Moreover, the restoration of DA transmission has been shown 
to be conducive to memory and learning in an AD mouse model reinforcing the role of DA 
in cognitive tasks [78,79]. This has recently been linked to a demonstrated protective role, 
where DA has anti-amyloidogenic and anti-oxidant effects in the mouse brain [24,80]. 
In summary, there are two distinct components connected with the memory modifying 
activity of S100A9 species in the aging mice within this study. Firstly, native S100A9 which 
is more likely to possess pro-inflammatory properties [16] did not modify memory in the 
passive avoidance task. This occurred even though it evoked a general and consistent 
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decrease in monoamine levels (DA, 5-HT and NA) and increased metabolic marker ratios of 
DA and 5-HT turnover (DOPAC/DA, HVA/DA and 5-HIAA) mainly in the prefrontal 
cortex. Secondly, S100A9 oligomers and fibrils administered separately induced amnesia 
accompanied by elevated DA turnover mainly in the hippocampus (Fig. 7) and though the 
fibrils did augment prefrontal cortical DA turnover, it was conceivable that this action was 
of secondary importance to the hippocampal response. The oligomer-fibril mixture behaved 
similarly to the fibrils administered alone but to a lesser degree and this may be attributable 
to the fact that both species in the mixture were matched to the total dose of the individual 
species in such a way that they were at half the combined concentration within the mixture. 
These results provide insight into a novel pathogenetic mechanism underlying amnesia in a 
fear-aggravated memory task based on amyloidogenesis of a pro-inflammatory agent 
leading to disrupted brain neurochemistry in the aged brain. The data further suggests that 
amyloid species of S100A9 generate deleterious activity principally to the DA-ergic system 
and this finding might be potentially exploited during dementia management through a 
neuroprotective strategy. 
 
 
Fig. 7. Scheme summarising the significant hippocampal and prefrontal cortical neurochemical 
outcomes of 14-day intranasal administration of S100A9 species in 12-month old C57Bl/6 mice in 
relation to their passive avoidance performance. 
Upward arrow = increase; downward arrow = decrease; horizontal double headed arrow = no change 
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